동아ST

Our Overseas Business Division

Leveraging successful product development and robust R&D capabilities,
Dong-A ST is actively expanding into new international markets.

The Overseas Business Division adopts an R&D-driven approach for global growth, focusing on securing new markets for its proprietary pipeline, which includes DA-3880, growth hormones, and diabetes treatments while maintaining its leadership in the domestic market. Additionally, the division seeks to boost its global presence through enhanced international marketing efforts.

Dong-A ST’s Overseas Business Division supplies key products such as Bacchus (energy drink) in Cambodia, Grotropin (growth hormone) in Brazil, and DA-3880 (anemia treatment) in Japan. In line with WHO tuberculosis guidelines, the company has expanded its supply of anti-tuberculosis drugs to regions including WHO programs, India, Russia, CIS, and South Africa, having obtained WHO Prequalification (PQ) for clofazimine. Furthermore, there is a growing demand for Evogliptin, a diabetes treatment, in markets like Russia and India.

To achieve its vision of becoming a global pharmaceutical leader, Dong-A ST is establishing strategic bases in key global markets, strengthening local sales capabilities, and expanding marketing reach. The company is focused on increasing exports of flagship products and expanding its portfolio across both developed and emerging markets. This includes developing innovative business models, entering advanced markets, adopting diversified recruitment strategies, and fostering global talent through comprehensive training programs, all aimed at solidifying Dong-A ST’s position as a world-class pharmaceutical company.

Global Partnership

North America :: USA

South America :: Guatemala, Brazil, Argentina, Chile

Oceania :: Guam, Saipan, New Zealand

Europe :: UK, Germany, France, Netherlands, Spain, World Health Organization (WHO), Turkey, Ukraine, Russia, Georgia,
Commonwealth of Independent States

Asia :: Malaysia, Mongolia, Myanmar, Bangladesh, Vietnam, Singapore, India, Japan, China, Cambodia, Thailand, Pakistan,
Philippines, Indonesia, Kazakhstan, Laos, Sri Lanka, North Korea

The Middle East and Africa :: Jordan, United Arab Emirates, Namibia, Morocco, Botswana, Syria, Algeria, Iraq, Saudi Arabia,
Nigeria, South Africa, Ghana, Iran

Importers and Products

No.	Major Importer	Exported Products
1	USA	Bacchus
2	Cambodia	Bacchus
3	Brazil	Gritropin, Evogliptin
4	Argentina	Cycloserine, Evogliptin
5	Russia	Bacchus, Cycloserine, Terizidone, Evogliptin, Clofazimine
6	Mongolia	Gonadopin, Bacchus, Leucostim
7	Morocco	Eporon
8	Japan	Voriconazole, Darbepoetin, Cycloserine
9	Nigeria	Growtropin
10	Lebanon	Growtropin, Leucostim, Eporon
11	China	Closerin
12	WHO	Closerin, Lampremin
13	Philippines	Eporon, Leucostim, Suganon
14	Iraq	Gonadopin, Eporon
15	Turkey	Eporon, Leucostim
16	South Africa	Stillen
17	Pakistan	Eporon
18	Uzbekistan	Gonadopin, Growtropin, Zydena
19	India	Cycloserine, Terizidone, Evogliptin, Lampremin
20	Malaysia	Zydena
21	Kazakhstan	Zydena, Cycloserine
22	Algeria	Closerin, Growtropin
23	Georgia	Growtropin, Leucostim, Eporon
24	Ukraine	Stillen, Growtropin, Zydena
25	Taiwan	Cycloserine, Suganon
26	Mexico	Morititone
27	Saudi Arabia	Growtropin
28	UAE	Growtropin, Leucostim, Eporon
29	UK	Closerin
30	Lithuania	Stillen
31	Indonesia	Eporon
32	Yemen	Eporon
Total	32 Countries	16 Products

New drugs

Stillen

Artemisia herb extract
Treatment for gastritis

Zydena

Udenafil
Treatment for erectile dysfunction

Motilitone

Corydaline (marker compound)
Corydails tuber, Pharbitis seed (5:1) 50% Ethanol extract, 30mg
Treatment for functional dyspepsia

Suganon

Evogliptin
Treatment for diabetes
Biologics

Gonadopin

Recombinant follitropin
Treatment for infertility

Eporon

Recombinant erythropoietin
Treatment for anemia in patients with chronic renal failure
1. Symptomatic anemia
2. Anemia requiring transfusion

Growtropin

Recombinant somatropin
Treatment for growth hormone deficiency

Leucostim

Recombinant filgrastim
1. Treatment of neutropenia in patients undergoing chemotherapy for solid tumors
2. Treatment of neutropenia in patients with hematologic malignancies
(acute myeloid leukemia) who are undergoing chemotherapy
3. Mobilization of hematopoietic stem cells into peripheral blood
4. Post-chemotherapy treatment for mobilization of autologous peripheral blood stem cells
5. Stimulant to increase neutrophil count during hematopoietic stem cell transplantation

DA-3880

Darbepoetin
Treatment for anemia
Generics

Closerin

Cycloserine
Treatment for tuberculosis

Lampremin

Clofazimine
Treatment for tuberculosis
Drug Substance

Cycloserine

Treatment for tuberculosis

Clofazimine

Treatment for tuberculosis

Evogliptin

Treatment for diabetes

Voriconazole

Treatment for fungal infections

Atorvastatin

Treatment for hyperlipidemia

Energy Drinks/Beverages

Bacchus

Energy drink containing taurine and vitamin b complex

Bacchus Sugar-Free

Sugar-free energy drink containing taurine and vitamin b complex

Bacchus-X

Energy drink containing taurine and ginseng extract

Vitagrand C

Vitamin C drink

Morning Care

Hangover remedy (Gmt-alc 5l 1,600 mg, Milk Thistle)
OTC Products/Nutritional Supplements

Garglin/Children’s
Garglin

Mouthwash

Champ

Cold medicine for children

Benachio

Digestive aid

Acnon Cream
(Acne Ointment)

Topical acne agent

Melatoning Cream

Blemishes and pigmentation cream

PANPYRIN

Antipyretic analgesic

MiNiMAX

Health supplement for children

Medicine Accessibility

Entry in the Medical Market

Dong-A ST is currently exporting novel drugs, generics, and biologics produced in cGMP facilities to 32 countries worldwide through its globally competitive overseas business network.
We have bases in the US, India, and China through which are exploring new market opportunities and expanding our global presence.

We are building a globally competitive pipeline through strategic investments and acquisitions of US pharmaceutical companies, and exploring further opportunities in the US and advanced markets.
India is one of our important bases for global expansion, through which we are exploring opportunities not only in the Indian market but in neighbouring ones.
Our Chinese subsidiary supplies antitubercular medications and supports production of other globally competitive products through partnerships with local CDMOs and clients to ensure a stable supply of drug substances.
Eradication of Global Tuberculosis

As a Stop TB Partner, Dong-A ST is committed to eliminating tuberculosis as a public health problem.
We are the world's largest WHO-qualified supplier of TB medicines, cycloserine and clofazimine, and have continuously lowered our prices for wider accessibility to treatment especially in underdeveloped and developing countries.
We are currently establishing a local production model in developing countries through technology transfer to reduce the treatment costs for more
tuberculosis patients.
Supporting Local Health

Dong-A ST engages in various CSR activities for sustainable development
and social value creation.

As a pharmaceutical manufacturer, we unite with local partners and NGOs
to make progress in areas with underdeveloped medical infrastructure.

We donate medicines and daily necessities to hospitals, schools, and
orphanages in Cambodia, navigating the path to better health for local
communities and educational environments for future talents.
In Ethiopia, we are making healthcare accessible to those facing barriers
through provision of our Hicardi ECG monitoring device together with the
Myungsung Christian Medical Center.

Our effort and innovation continue, to expand our CSR activities both
domestically and globally for a better society.
Improving Access to Medicines - Cost Transparency

Dong-A ST is improving access to essential medicines in underdeveloped countries by supplying WHO-certified TB drugs to WHO and high TB burden countries.

By participating in WHO tenders, we are transparently disclosing our supply prices and contributing toward lowering social costs for global tuberculosis eradication. For non-WHO member countries, we set our prices in consideration of their TB treatment strategies and budget.

We are also working with the WHO on a new TB treatment that is currently under review by the WHO, which will lessen the economic burden and enable more patients to access treatment.
Improving Access to Medicines – Supply Chain Improvements

To ensure the quality of medicines supplied overseas, Dong-A ST conducts thorough evaluation to select partners capable of local production and quality/distribution management.
We provide the necessary technical support to our partners to ensure a stable supply of raw materials and pharmaceuticals.

We sincerely consider local production and technology transfers upon request from our partners and developing countries.
We have been transferring Korea's advanced pharmaceutical manufacturing technology (such as ED medication and diabetic treatments) to developing countries including Jordan and Tunisia.

At the same time, we have been improving the quality and supply of pharmaceuticals in the neighbouring countries by expanding the supply channel through local production.
Improving Access to Medicines – Post-Market Surveillance

Dong-A ST works closely with all partners to continuously monitor and evaluate adverse drug reactions in developing countries.
We have established a global database that collects data on the safety of marketed medicines.
This allows for analysis of risks and benefits, and aids our partners in meeting regulatory requirements.

Our partners have the capabilities to organize all activities related to pharmacovigilance and post-marketing surveillance.